During the last session, Aligos Therapeutics Inc (NASDAQ:ALGS)’s traded shares were 0.38 million, with the beta value of the company hitting 2.50. At the end of the trading day, the stock’s price was $43.42, reflecting an intraday gain of 9.04% or $3.6. The 52-week high for the ALGS share is $44.39, that puts it down -2.23 from that peak though still a striking 84.43% gain since the share price plummeted to a 52-week low of $6.76. The company’s market capitalization is $155.79M, and the average intraday trading volume over the past 10 days was 0.49 million shares, and the average trade volume was 397.84K shares over the past three months.
Aligos Therapeutics Inc (ALGS) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.00. ALGS has a Sell rating from 2 analyst(s) out of 9 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Aligos Therapeutics Inc (NASDAQ:ALGS) trade information
Aligos Therapeutics Inc (ALGS) registered a 9.04% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 9.04% in intraday trading to $43.42, hitting a weekly high. The stock’s 5-day price performance is 0.12%, and it has moved by 62.32% in 30 days. Based on these gigs, the overall price performance for the year is 134.70%. The short interest in Aligos Therapeutics Inc (NASDAQ:ALGS) is 0.46 million shares and it means that shorts have 0.88 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies a decrease of -1347.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $3 respectively. As a result, ALGS is trading at a premium of 93.09% off the target high and 93.09% off the low.
Aligos Therapeutics Inc (ALGS) estimates and forecasts
Statistics show that Aligos Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Aligos Therapeutics Inc (ALGS) shares have gone up 329.79% during the last six months, with a year-to-date growth rate more than the industry average at 69.53% against 16.80.
While earnings are projected to return 70.31% in 2025.
ALGS Dividends
Aligos Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aligos Therapeutics Inc (NASDAQ:ALGS)’s Major holders
Aligos Therapeutics Inc insiders own 17.80% of total outstanding shares while institutional holders control 48.86%, with the float percentage being 59.44%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 34.0 institutions own stock in it. As of 2024-06-30, the company held over 7.26 million shares (or 4.6471% of all shares), a total value of $2.54 million in shares.
The next largest institutional holding, with 6.39 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 4.0919% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.24 million.
